Abbott secures UPC injunction in diabetes monitoring device appeal against Chinese rival
By Inbar Preiss ( April 20, 2026, 09:48 GMT | Insight) -- Abbott Diabetes Care has secured a UPC injunction against Sinocare’s GlucoMen iCan, with appeal judges overturning a refusal and finding indirect infringement and likely validity. Judges cited urgency, warning that continued sales risked loss of market share and lasting price erosion.US healthcare company Abbott Diabetes Care has won a preliminary injunction against Chinese manufacturer Sinocare and its European distribution partner Menarini at the Unified Patent Court, after appellate judges overturned an earlier decision and found Abbott’s glucose-monitoring patent infringed and likely valid....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.